Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IST:MEDTR's PB Ratio is ranked better than 85.11% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs IST:MEDTR: 0.80
During the past 12 months, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's average Book Value Per Share Growth Rate was 64.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 24.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 68.30% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of MEDITERA TIBBI MALZEMENAYI VE TICARET AS was 182.10% per year. The lowest was 24.50% per year. And the median was 114.80% per year.
Back to Basics: PB Ratio
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS PB Ratio Related Terms
MEDITERA TIBBI MALZEMENAYI VE TICARET AS PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS PB Ratio Chart
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Annual Data
For the Medical Devices subindustry, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where MEDITERA TIBBI MALZEMENAYI VE TICARET AS's PB Ratio falls into.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) has a PB Ratio of 0.81 as of Jul. 23, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. This is 67% below median its historical median of 2.49. Over the past decade, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's PB Ratio has ranged from 0.80 to 8.33. According to the industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #117 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 14.9%.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS's PB Ratio too high?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current PB Ratio of 0.81 is 67% below median its 10-year median of 2.49. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 8.33. The Medical Devices & Instruments industry median PB Ratio is 2.02. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 0.81 is 59.9% below this industry median. Based on the distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #117 out of 786 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDITERA TIBBI MALZEMENAYI VE TICARET AS's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #117 out of 786 companies for PB Ratio. This places MEDITERA TIBBI MALZEMENAYI VE TICARET AS in the top 15% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.02. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 0.81 is 59.9% below this benchmark. Historically, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's own PB Ratio has ranged from 0.80 to 8.33 over the past decade. While the company's 10-year median is 2.49 vs. the industry median of 2.02, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current PB Ratio of 0.81 is 59.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current PB Ratio is 0.81, which is 67% below median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock overvalued right now?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₺44.03, compared to a current price of ₺26.78 — trading 39.2% below its estimated fair value. The current PB Ratio is 0.81, which is 67% below median its 10-year median of 2.49 and 59.9% below the Medical Devices & Instruments industry median of 2.02. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR), the current PB Ratio is 0.81 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Overvalued in 2026?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock appears to be undervalued.
The current stock price of ₺26.78 is trading 39.2% below its estimated GF Value™ of ₺44.03.
GuruFocus considers MEDITERA TIBBI MALZEMENAYI VE TICARET AS to be Significantly Undervalued.
Key valuation signals for IST:MEDTR:
PB Ratio: 0.81 (67% below median its 10-year median of 2.49)
GF Value™: ₺44.03 vs. price of ₺26.78 (39.2% below fair value)
Industry Position: 59.9% below the Medical Devices & Instruments median (#117 of 786)
No single metric tells the full story. See the IST:MEDTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Business Description
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
79GF Score
Get the complete analysis for IST:MEDTR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:MEDTR has been successfully added to your 
